Exclusive Summary

• The product boasts US FDA GMP certification and USP API compliance, with existing US registration, providing globally recognized quality and regulatory advantages for rapid market entry.
• The nasal spray dosage form offers superior patient adherence and convenience compared to injections, particularly for long-term treatment of Vitamin B12 deficiency.
• As an already US-registered generic drug, it enters the market post-patent expiration, offering a mature product with a cost advantage, positioning it well in the global generic market.
• Vitamin B12 deficiency, a common global condition, ensures stable and substantial market demand for cyanocobalamin nasal spray.